Table 2 Univariate analysis for associations of variables with tamoxifen failure at 5 years, disease-free survival and disease-specific survival for entire study period

Age <50

16

1.00

1.00

1.00

Age ≥50

175

0.49 (0.22, 1.08)

0.08

0.69 (0.33, 1.46)

0.33

0.79 (0.33, 1.87)

0.58

Tumor size ≤2 cm

105

1.00

1.00

1.00

Tumor size >2 cm

86

1.92 (1.08, 3.42)

0.03

1.95 (1.18, 3.24)

0.01

2.39 (1.32, 4.31)

0.004

Tumor grade 1

15

1.00

1.00

1.00

Tumor grade 2

112

1.78 (0.42, 7.54)

0.43

1.33 (0.47, 3.74)

0.59

1.05 (0.37, 3.02)

0.92

Tumor grade 3

63

3.33 (0.78, 14.2)

0.10

2.05 (0.71, 5.90)

0.18

1.52 (0.51, 4.51)

0.45

LN-negative

63

1.00

1.00

1.00

LN-positive

83

3.41 (1.40, 8.31)

0.01

2.42 (1.19, 4.94)

0.02

2.12 (0.95, 4.75)

0.07

%ER, continuous

192

0.98 (0.98, 0.99)

0.0002

0.99 (0.98, 0.99)

0.0004

0.99 (0.98, 0.99)

0.001

AR = 0%

20

1.00

1.00

1.00

AR >0%

171

0.61 (0.27, 1.36)

0.23

0.91 (0.42, 2.01)

0.82

1.20 (0.43, 3.33)

0.73

AR/ER < 2

169

1.00

1.00

1.00

AR/ER ≥ 2

22

4.43 (2.33, 8.42)

<0.0001

4.40 (2.47, 7.83)

<0.0001

3.66 (1.94, 6.93)

<0.0001

PR-negative

22

1.00

1.00

1.00

PR-positive

108

0.43 (0.18, 1.04)

0.06

0.62 (0.27, 1.43)

0.26

0.69 (0.26, 1.84)

0.46

MIB-1 <21.3

93

1.00

1.00

1.00

MIB-1 ≥21.3

95

1.17 (0.66, 2.07)

0.59

0.98 (0.59, 1.61)

0.93

0.98 (0.55, 1.73)

0.94

Mitotic index number ≤4

94

1.00

1.00

1.00

Mitotic index number >4

92

1.64 (0.92, 2.94)

0.10

1.54 (0.93, 2.55)

0.10

1.34 (0.77, 2.37)

0.30

erbB2 ≤30%

152

1.00

1.00

1.00

erbB2 >30%

16

1.02 (0.36, 2.84)

0.98

0.71 (0.26, 1.96)

0.51

0.69 (0.22, 2.24)

0.54

EGFR = 0%

139

1.00

1.00

1.00

EGFR >0%

26

1.31 (0.60, 2.83)

0.50

1.01 (0.50, 2.07)

0.97

1.17 (0.54, 2.51)

0.70